|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma显示文摘AIM: To assess the clinical features and prognosis of 151 patients with extrahepatic metastases from primary hepatocellular carcinoma (HCC), and describe the treatment strategy for such patients. METHODS: After the diagnosis of HCC, all 995 consecutive HCC patients were followed up at regular intervals and 151 (15.2%) patients were found to have extrahepatic metastases at the initial diagnosis of primary HCC or developed such tumors during the follow-up period. We assessed their clinical features, prognosis, and treatment strategies. RESULTS: The most frequent site of extrahepatic metastases was the lungs (47%), followed by lymph nodes (45%), bones (37%), and adrenal glands (12%). The cumulative survival rates after the initial diagnosis of extrahepatic metastases at 6, 12, 24, and 36 mo were 44.1%, 21.7%, 14.2%, 7.1%, respectively. The median survival time was 4.9 mo (range, 0-37 mo). Fourteen patients (11%) died of extrahepatic HCC, others died of primary HCC or liver failure. CONCLUSION: The prognosis of HCC patients with extrahepatic metastases is poor. With regard to the cause of death, many patients would die of intrahepatic HCC and few of extrahepatic metastases. Although most of HCC patients with extrahepatic metastases should undergo treatment for the primary HCC mainly, treatment of extrahepatic metastases in selected HCC patients who have good hepatic reserve, intrahepatictumor stage (T0-T2), and are free of portal venous invasion may improve survival. | Kiminori Uka Hiroshi Aikata Shintaro Takaki Hiroo Shirakawa Soo Cheol Jeong Keitaro Yamashina Akira Hiramatsu Hideaki Kodama Shoichi Takahashi Kazuaki Chayama | 2007 | World Journal of Gastroenterology2007，13，3： | 44 |
| 2 | Petawatt and exawatt class lasers worldwide显示文摘In the 2015 review paper‘Petawatt Class Lasers Worldwide’a comprehensive overview of the current status of highpower facilities of>200 TW was presented.This was largely based on facility specifications,with some description of their uses,for instance in fundamental ultra-high-intensity interactions,secondary source generation,and inertial confinement fusion(ICF).With the 2018 Nobel Prize in Physics being awarded to Professors Donna Strickland and Gerard Mourou for the development of the technique of chirped pulse amplification(CPA),which made these lasers possible,we celebrate by providing a comprehensive update of the current status of ultra-high-power lasers and demonstrate how the technology has developed.We are now in the era of multi-petawatt facilities coming online,with 100 PW lasers being proposed and even under construction.In addition to this there is a pull towards development of industrial and multi-disciplinary applications,which demands much higher repetition rates,delivering high-average powers with higher efficiencies and the use of alternative wavelengths:mid-IR facilities.So apart from a comprehensive update of the current global status,we want to look at what technologies are to be deployed to get to these new regimes,and some of the critical issues facing their development. | Colin N.Danson Constantin Haefner Jake Bromage Thomas Butcher Jean-Christophe FChanteloup Enam A.Chowdhury Almantas Galvanauskas Leonida A.Gizzi Joachim Hein David I.Hillier Nicholas W.Hopps Yoshiaki Kato Efim A.Khazanov Ryosuke Kodama Georg Korn Ruxin Li Yutong Li Jens Limpert Jingui Ma Chang Hee Nam David Neely Dimitrios Papadopoulos Rory R.Penman Liejia Qian Jorge J.Rocca andrey A.Shaykin Craig W.Siders Christopher Spindloe Sándor Szatmári Raoul M.G.M.Trines Jianqiang Zhu Ping Zhu Jonathan D.Zuegel | 2019 | High Power Laser Science and Engineering2019，7，3： | 33 |
| 3 | Latest insights into the effects of Helicobacter pylori infection on gastric carcinogenesis显示文摘看起来是在 Helicobacter pylori (H pylori ) 和胃的癌症之间的强壮的协会。我们在胃的致癌作用上关于 H pylori 感染的效果考察了最近的证据,分类进传染病学,胃的粘膜变化的动力学, DNA 损坏,毒力因素,主人因素,和胃的恶意的来源。通过在对源于 H pylori 紧张之间的差别的毒力因素的研究取得的可观的进步,例如 cagA 确实,以及进主人因素,例如基因多型性,包括胃的癌症, H 联系 pylori 的疾病的一个多样的系列把自己正在借给说明。当发展研究上的胃的恶意的潜在的来源与兴趣尚待分晓,建议骨头髓的 Houghton 等推进的新奇假设的影响导出干细胞(BMDC ) 。进一步作为胃的癌症的可行预防在对 H pylori 根除,以及进胃的致癌作用的机制的研究进行,是急切地被等候当前的年并且在以外。 | Kazunari Murakami Masaaki Kodama Toshio Fujioka | 2006 | World Journal of Gastroenterology2006，12，17： | 20 |
| 4 | Helicobacter pylori-infected animal models are extremely suitable for the investigation of gastric carcinogenesis显示文摘Although various animal models have been developed to clarify gastric carcinogenesis, apparent mechanism of gastric cancer was not clarified in recent years. Since the recognition of the pathogenicity of Helicobacter pylori (Hpylori), several animal models with Hpylori infection have been developed to confirm the association between Hpylori and gastric cancer. Nonhuman primate and rodent models were suitable for this study. Japanese monkey model revealed atrophic gastritis and p53mutation after long-term infection of Hpylori. Mongolian gerbil model showed the development of gastric carcinoma with H pylori infection alone, as well as with combination of chemical carcinogens, such as N-methylN-nitrosourea and N-methyl-N-nitro-N'-nitrosoguanidine.The histopathological changes of these animal models after Hpylori inoculation are closely similar to those in human beings with Hpylori infection. Eradication therapy attenuated the development of gastric cancer in Hpyloriinfected Mongolian gerbil. Although several features of animal models differ from those seen in human beings,these experimental models provide a starting point for further studies to clarify the mechanism of gastric carcinogenesis as a result of Hpylori infection and assist the planning of eradication therapy to prevent gastric carcinoma. | Masaaki Kodama Kazunari Murakami Ryugo Sato Tadayoshi Okimoto Akira Nishizono Toshio Fujioka | 2005 | World Journal of Gastroenterology2005，11，45： | 19 |
| 5 | Expression of mutant type-p53 products in H pylori-associated chronic gastritis显示文摘AIM:To investigate the mutation of p 53 immuno-histochemically in non-tumorous gastric mucosa with H pylori infection before and after H pylori eradication therapy.METHODS:53 subjects(36 male,17 female,mean age ± SEM,57.1 ± 12.1)undergoing endoscopic examination were included in this study.42 of 53 patients were H pylori-positive,and 11 were H pylori-negative.All H pylori-positive patients had successful eradication therapy.Biopsy specimens were taken from five points of the stomach,as recommended by the updated Sydney system.Immunohistochemical studies were performed by using primary antibodies against p53(DO-7 and PAb240).RESULTS:p53(DO-7 and PAb240)immunoreactivity was shown in the neck region of the gastric pits,however,quite a few cells were found to be immunopositive for p 53(PAb240)in the H pylori-infected gastric mucosa.The proportion of patients immunopositive for p 53(PAb240)was significantly reduced 6 mo after eradication [28/42(66.7%)to 6/42(14.3%)](P < 0.05),while the biopsies taken from H pylori-negative patients showed no immunoreactivity for p53(PAb240).p53(PAb240)-positive patients were divided into two groups by the number of positive cells detected:one with more than six positive cells per 10 gastric pits(group A,n = 12),and the other with less than five positive cells per 10 gastric pits(group B,n = 30).Atrophy scores in group A were significant higher than those in group B at the greater curvature of the antrum(group A:2.00 ± 0.14 vs group B:1.40 ± 0.15,P = 0.012),the lesser curvature of the corpus(group A:2.00 ± 0.21 vs group B:1.07 ± 0.23,P = 0.017),and the greater curvature of the corpus(group A:1.20 ± 0.30vs group B:0.47 ± 0.21,P = 0.031).Group A showed significant higher intestinal metaplasia scores than group B only at the lesser curvature of the antrum(group A:2.10 ± 0.41 vs group B:1.12 ± 0.29,P = 0.035).CONCLUSION:H pylori-associated chronic gastritis expressed the mutant-type p53,which was significantly associated with more severe atrophic and metaplastic changes.H pylori eradication led to a significant reduction in the expression of the mutant-type p53.It is considered that H pylori-infected chronic gastritis is associated with a genetic instability that leads to gastric carcinogenesis,and H pylori eradication may prevent gastric cancer. | Masaaki Kodama Kazunari Murakami Tadayoshi Okimoto Ryugo Sato Koichiro Watanabe Toshio Fujioka | 2007 | World Journal of Gastroenterology2007，13，10： | 13 |
| 6 | 黄果茄果实杀螺成分的分离和结构解析显示文摘黄果茄在长江中下游血吸虫病疫区分布广泛。从黄果茄果实中提取分离出一种新的具有灭螺活性的化合物,相对分子质量是772,分子式为C39H64O11N;通过化学和光谱方法解析了结构,含澳洲茄碱的骨架。该化合物浸杀钉螺成螺实验结果表明,在质量浓度达到0.5800mg/L,浸杀48h,钉螺致死率达到100%。 | 李文新 黄雪英 祁超 刘实 Osamu Kodama Kuchhi Utaka | 2007 | 农药2007，46，9： | 9 |
| 7 | Clinical outcomes of ampullary neoplasms in resected margin positive or uncertain cases after endoscopic papillectomy显示文摘BACKGROUND Endoscopic papillectomy(EP) for benign ampullary neoplasms could be a lessinvasive alternative to pancreatoduodenectomy(PD). There are some problems and limitations with EP. The post-EP resection margins of ampullary tumors are often positive or uncertain because of the burning effect of EP. The clinical outcomes of resected margin positive or uncertain cases after EP remain unknown.AIM To investigate the clinical outcomes of resected margin positive or uncertain cases after EP.METHODS Between January 2007 and October 2018, all patients with ampullary tumors who underwent EP at Kobe University Hospital were included in this study. The indications for EP were as follows: adenoma, as determined by preoperative endoscopic biopsy, without bile/pancreatic duct extension, according to endoscopic ultrasound or intraductal ultrasound. The clinical outcomes of resected margin positive or uncertain cases after EP were retrospectively investigated.RESULTS Of the 45 patients, 29 were male, and 16 were female. The mean age of the patients was 65 years old. Forty-one patients(89.5%) underwent en bloc resection,and 4 patients(10.5%) underwent piecemeal resection. After EP, 33 tumors were histopathologically diagnosed as adenoma, and 12 were diagnosed as adenocarcinoma. The resected margins were positive or uncertain in 24 patients(53.3%). Of these cases, 15 and 9 were diagnosed as adenoma and adenocarcinoma, respectively. Follow-up observation was selected for all adenomas and 5 adenocarcinomas. In the remaining 4 adenocarcinoma cases,additional PD was performed. Additional PD was performed in 4 cases, and residual carcinoma was found after the additional PD in 1 of these cases. In the follow-up period, local tumor recurrence was detected in 3 cases. Two of these cases involved primary EP-diagnosed adenoma. The recurrent tumors were also adenomas detected by biopsy. The remaining case involved primary EPdiagnosed adenocarcinoma. The recurrent tumor was also an adenocarcinoma.All of the recurrent tumors were successfully treated with argon plasma coagulation(APC). There was no local or lymph node recurrence after the APC.The post-APC follow-up periods lasted for 57.1 to 133.8 mo. No ampullary tumor-related deaths occurred in all patients.CONCLUSION Resected margin positive or uncertain cases after EP could be managed by endoscopic treatment including APC, even in cases of adenocarcinoma. EP could become an effective less-invasive first-line treatment for early stage ampullary tumors. | Arata Sakai Masahiro Tsujimae Atsuhiro Masuda Takao Iemoto Shigeto Ashina Kohei Yamakawa Takeshi Tanaka Shunta Tanaka Yasutaka Yamada Ryota Nakano Yu Sato Manabu Kurosawa Takuya Ikegawa Seiji Fujigaki Takashi Kobayashi Hideyuki Shiomi Yoshifumi Arisaka Tomoo Itoh Yuzo Kodama | 2019 | World Journal of Gastroenterology2019，25，11： | 9 |
| 8 | Aspirin-induced small bowel injuries and the preventive effect of rebamipide显示文摘AIM:To evaluate the influence of taking low-dose aspirin for 4 wk on small intestinal complications and to examine the preventive effect of rebamipide.METHODS:This study was conducted as a single-center,randomized,double-blind,cross-over,placebo-controlled study.Eleven healthy male subjects were enrolled.Each subject underwent video capsule endos-copy after 1 and 4 wk of taking aspirin and omepra-zole,along with either rebamipide or placebo therapy.The primary endpoint was to evaluate small bowel damage in healthy subjects before and after taking low-dose aspirin for 4 wk.RESULTS:The number of subjects with mucosal breaks(defined as multiple erosions and/or ulcers)were 1 at 1 wk and 1 at 4 wk on the jejunum,and 6 at 1 wk(P = 0.0061)and 7 at 4 wk on the ileum(P =0.0019).Rebamipide significantly prevented mucosal breaks on the ileum compared with the placebo group(P = 0.0173 at 1 wk and P = 0.0266 at 4 wk).CONCLUSION:Longer-term,low-dose aspirin adminis-tration induced damage in the small bowel.Rebamipide prevented this damage,and may be a candidate drug for treating aspirin-induced small bowel complications. | Kazuhiro Mizukami Kazunari Murakami Takashi Abe Kunimitsu Inoue Masahiro Uchida Tadayoshi Okimoto Masaaki Kodama Toshio Fujioka | 2011 | World Journal of Gastroenterology2011，17，46： | 8 |
| 9 | Influence of proton pump inhibitor treatment on Helicobacter pylori stool antigen test显示文摘AIM: To investigate the effects of proton pump inhibitor (PPI) treatment on stool antigen test using the TestMate pylori enzyme immunoassay. METHODS: This study assessed 28 patients [16 men and 12 women; mean age (63.1 ± 5.9) years; range, 25-84 years] who underwent stool antigen test and urea breath test (UBT) before and after PPI administration. RESULTS: Using the UBT as the standard, the sensitivity, specif icity and agreement of the stool antigen test in all 28 patients were 95.2%, 71.4%, and 89.3%, respectively, before PPI administration, and 88.9%, 90.9%, and 89.3%, respectively, after PPI treatment. Mean UBT values were 23.98% ± 5.33% before and 16.19% ± 4.75% after PPI treatment and, in 15 patients treated for ≥ 4 wk, were signif icantly lower after than before 4 wk of PPI treatment (12.58% ± 4.49% vs 24.53% ± 8.53%, P = 0.048). The mean optical density (A450/630) ratios on the stool antigen test were 1.16 ± 0.20 before and 1.17 ± 0.24 after PPI treatment (P = 0.989), and were 1.02 ± 0.26 and 0.69 ± 0.28, respectively, in the group treated for > 4 wk (P = 0.099). | Masaaki Kodama Kazunari Murakami Tadayoshi Okimoto Yoshihiro Fukuda Tadashi Shimoyama Masumi Okuda Chieko Kato Intetsu Kobayashi Toshio Fujioka | 2012 | World Journal of Gastroenterology2012，18，1： | 7 |
| 10 | A novel negative regulatory mechanism of Smurf2 in BMP/Smad signaling in bone显示文摘Transforming growth factor-β(TGF-β)and bone morphogenetic protein(BMP)play important roles in bone metabolism.Smad ubiquitination regulatory factors(Smurfs)regulate TGF-β/BMP signaling via ubiquitination,resulting in degradation of signaling molecules to prevent excessive activation of TGF-β/BMP signaling.Though Smurf2 has been shown to negatively regulate TGF-β/Smad signaling,its involvement in BMP/Smad signaling in bone metabolism has not been thoroughly investigated.In the present study,we sought to evaluate the role of Smurf2 in BMP/Smad signaling in bone metabolism.Absorbable collagen sponges containing 3μg of recombinant human BMP2(rhBMP2)were implanted in the dorsal muscle pouches of wild type(WT)and Smurf2−/−mice.The rhBMP2-induced ectopic bone in Smurf2−/−mice showed greater bone mass,higher mineral apposition and bone formation rates,and greater osteoblast numbers than the ectopic bone in WT mice.In WT mice,the ectopic bone consisted of a thin discontinuous outer cortical shell and scant inner trabecular bone.In contrast,in Smurf2−/−mice,the induced bone consisted of a thick,continuous outer cortical shell and abundant inner trabecular bone.Additionally,rhBMP2-stimulated bone marrow stromal cells(BMSCs)from Smurf2−/−mice showed increased osteogenic differentiation.Smurf2 induced the ubiquitination of Smad1/5.BMP/Smad signaling was enhanced in Smurf2−/−BMSCs stimulated with rhBMP2,and the inhibition of BMP/Smad signaling suppressed osteogenic differentiation of these BMSCs.These findings demonstrate that Smurf2 negatively regulates BMP/Smad signaling,thereby identifying a new regulatory mechanism in bone metabolism. | Junichi Kushioka Takashi Kaito Rintaro Okada Hiroyuki Ishiguro Zeynep Bal Joe Kodama Ryota Chijimatsu Melanie Pye Masahiro Narimatsu Jeffrey LWrana Yasumichi Inoue Hiroko Ninomiya Shin Yamamoto Takashi Saitou Hideki Yoshikawa Takeshi Imamura | 2020 | Bone Research2020，8，4： | 6 |
| 11 | Familial pancreatic cancer: Concept, management and issues显示文摘Familial pancreatic cancer (FPC) is broadly defined as two first-degree-relatives with pancreatic cancer (PC) and accounts for 4%-10% of PC. Several genetic syndromes, including Peutz-Jeghers syndrome, hereditary pancreatitis, hereditary breast-ovarian cancer syndrome(HBOC), Lynch syndrome, and familial adenomatous polyposis (FAP), also have increased risks of PC, but the narrowest definition of FPC excludes these known syndromes. When compared with other familial tumors, proven genetic alterations are limited to a small proportion (<20%) and the familial aggregation is usually modest. However, an ethnic deviation (Ashkenazi Jewish>Caucasian) and a younger onset are common also in FPC. In European countries, 'anticipation' is reported in FPC families, as with other hereditary syndromes; a trend toward younger age and worse prognosis is recognized in the late years. The resected pancreases of FPC kindred often show multiple pancreatic intraepithelial neoplasia (Pan IN) foci, with various K-ras mutations, similar to colorectal polyposis seen in the FAP patients. As with HBOC patients, a patient who is a BRCA mutation carrier with unresectable pancreatic cancer (accounting for 0%-19% of FPC patients) demonstrated better outcome following platinum and Poly (ADP-ribose) polymerase inhibitor treatment. Western countries have established FPC registries since the 1990 s and several surveillance projects for highrisk individuals are now ongoing to detect early PCs. Improvement in lifestyle habits, including non-smoking, is recommended for individuals at risk. In Japan, the FPC study group was initiated in 2013 and the Japanese FPC registry was established in 2014 by the Japan Pancreas Society. | Hiroyuki Matsubayashi Kyoichi Takaori Chigusa Morizane Hiroyuki Maguchi Masamichi Mizuma Hideaki Takahashi Keita Wada Hiroko Hosoi Shinichi Yachida Masami Suzuki Risa Usui Toru Furukawa Junji Furuse Takamitsu Sato Makoto Ueno Yoshimi Kiyozumi Susumu Hijioka Nobumasa Mizuno Takeshi Terashima Masaki Mizumoto Yuzo Kodama Masako Torishima Takahisa Kawaguchi Reiko Ashida Masayuki Kitano Keiji Hanada Masayuki Furukawa Ken Kawabe Yoshiyuki Majima Toru Shimosegawa | 2017 | World Journal of Gastroenterology2017，23，6： | 5 |
| 12 | Photothermal therapy of tumors in lymph nodes using gold nanorods and near-infrared laser light with controlled surface cooling显示文摘Photothermal 治疗(PTT ) 用在红外线附近(NIR ) 激光光和金 nanorods (GNR ) 作为一种新奇癌症治疗形式显示出诺言。然而,要求破坏肿瘤房间的激光紧张在皮肤下面定位了比阀值紧张大那原因皮肤损坏;因此,有激光光的照耀损坏皮肤以及肿瘤。这里,我们证明一个温度控制系统允许变形淋巴节点(行) 被 PTT 用 NIR 激光光和 GNR 对待,没有皮肤损坏。行转移的一个老鼠模型被肿瘤房间的注射开发,并且忍受肿瘤的合适的腋的行在 GNR 的注射以后与 NIR 激光光被对待。皮肤温度在 45 点被维持。潮湿转移能力索引(h D A/P ) 最大因为 30essure (BP ) ,心率(HR ) 和官方补给的症状在 270min 上被估计。 | Tessai Sugiura Daisuke Matsuki Junnosuke Okajima Atsuki Komiya Shiro Mori Shigenao Maruyama Tetsuya Kodama | 2015 | Nano Research2015，8，12： | 5 |
| 13 | Influence of bile reflux and Helicobacter pylori infection on gastritis in the remnant gastric mucosa after distal gastrectomy显示文摘 | Hisanori Abe Kazunari Murakami Shunzo Satoh Ryugo Sato Masaaki Kodama Tsuyoshi Arita Toshio Fujioka | 2005 | Journal of Gastroenterology2005，，6： | 4 |
| 14 | Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication显示文摘 | Masaaki Kodama Kazunari Murakami Tadayoshi Okimoto Ryugo Sato Masahiro Uchida Takashi Abe Seiji Shiota Yoshifumi Nakagawa Kazuhiro Mizukami Toshio Fujioka | 2012 | Journal of Gastroenterology2012，，4： | 4 |
| 15 | Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice显示文摘 | Kouichi Miura Yuzo Kodama Sayaka Inokuchi Bernd Schnabl Tomonori Aoyama Hirohide Ohnishi Jerrold M. Olefsky David A. Brenner Ekihiro Seki | 2010 | Gastroenterology2010，，1： | 3 |
| 16 | Microscopic evidence for the intra-unit-cell electronic nematicity inside the pseudogap phase in YBa_(2)Cu_(4)O_(8)显示文摘Understanding the nature of the mysterious pseudogap phenomenon is one of the most important issues associated with cuprate high-T_(c) superconductors.Here,we report 17O nuclear magnetic resonance(NMR) studies on two planar oxygen sites in stoichio?metric cuprate YBa_(2)Cu_(4)O_(8) to investigate the symmetry breaking inside the pseudogap phase.We observe that the Knight shifts of the two oxygen sites are identical at high temperatures but different below T_(nem) ~185 K,which is close to the pseudogap temperature T^(*).Our result provides a microscopic evidence for intra-unit-cell electronic nematicity.The difference in quadrupole resonance frequency between the two oxygen sites is unchanged below T_(nem),which suggests that the observed nematicity does not directly stem from the local charge density modulation.Furthermore,a short-range charge density wave(CDW) order is observed below T=150 K.The additional broadening in the 17O-NMR spectra because of this CDW order is determined to be inequivalent for the two oxygen sites,which is similar to that observed in case of nematicity.These results suggest a possible connection between nematicity,CDW order,and pseudogap. | Wen Wang Jun Luo ChunGuang Wang Jie Yang Yasuharu Kodama Rui Zhou Guo-Qing Zheng | 2021 | Science China(Physics,Mechanics & Astronomy)2021，64，3： | 3 |
| 17 | 岩石磁组构可以揭示应变吗?--以华南地块早三叠世灰岩为例显示文摘一般认为磁组构能有效地反映岩石所经历的应变特征.为了研究不同类型的磁组构和不同期次应变之间的关系,对来自华南地块两个地区的早三叠世灰岩样品进行了岩石磁学、磁组构以及应变特征的对比分析来自湖北通山县的样品经历了三期构造变形,这为解析磁组构和多期次应变提供了理想的机会.岩石磁学结果显示携磁矿物主要为磁铁矿.磁化率各向异性(AMS)和非磁滞剩磁各向异性(AAR)结果显示其最小轴与层面垂直,最大轴和中间轴分布于层面内,反映了沉积和压实作用产生的应变,而后期构造应变在磁组构中没有体现.来自广东连县的样品发育有渗透性压溶缝面理和方解石脉,说明经历了构造应变.AMS结果没有显示占优势的组构方向.AAR结果显示三轴组构,其最大轴分布于最大应力方位,与构造应变特征吻合,最初的压实组构被构造应变组构所代替.上述结果表明:(1) AAR可以很好地反映渗透性应变的特征,而AMS有时会失效;(2)应变的尺度要小于样品的尺度,磁组构才能有效地反映应变. | 韩玉林 谈晓冬 Kenneth P. Kodama | 2009 | 地球物理学报2009，52，10： | 3 |
| 18 | Immunohistochemical expression of thymidylate synthase and prognosis in gastric cancer patients submitted to fluoropyrimidine-based chemotherapy显示文摘Objective: Adjuvant chemotherapy with 5-fluorouracil(5-FU) has been widely used in gastric cancer(GC)patients to prevent relapse after curative resection. 5-FU acts by inhibiting thymidylate synthase(TS), and high levels of TS correlate with resistance to treatment with fluoropyrimidines. The aim of this study was to evaluate the expression of TS in GC patients, and its relation with clinicopathological characteristics and prognosis in adjuvant chemotherapy with 5-FU.Methods: We retrospectively evaluated 285 patients who underwent D2-gastrectomy with curative intent. TS expression was determined by immunohistochemistry(IHC) in tumor cells by tissue microarray(TMA). TS level was evaluated according to the intensity and percentage of cells marked by a score system. Patients were divided in three groups according to their TS-score: negative, low and high.Results: TS expression was positive in 92.3% of GC. TS-high, TS-low and TS-negative were observed in46.3%, 46.0% and 7.7% of patients, respectively. High-TS GC were associated with older age(P=0.007), high neutrophil/lymphocyte ratio(P=0.048), well/moderately differentiated histology(P=0.001), intestinal Lauren type(P<0.001) and absence of perineural invasion(P=0.003). Among 285 patients, 133 stage Ⅱ/Ⅲ patients(46.7%)received chemotherapy with 5-FU. In survival analysis, TS-high was associated with worse disease-free survival(DFS) in stage Ⅲ GC patients who received 5-FU-based chemotherapy(P=0.007). Multivariate analysis revealed that total gastrectomy, poorly differentiated tumors and high TS-score were associated with worse DFS in stage Ⅲ GC patients.Conclusions: High TS-score in stage Ⅲ GC was associated with poor DFS in patients treated with fluoropyrimidine-based chemotherapy. | Marina Alessandra Pereira Marcus Fernando Kodama Pertille Ramos ANDre Roncon Dias Sheila Friedrich Faraj Cinthya dos Santos Cirqueira EvANDro Sobroza de Mello Bruno Zilberstein Venancio Avancini Ferreira Alves Ulysses Ribeiro Jr | 2018 | Chinese Journal of Cancer Research2018，30，5： | 3 |
| 19 | Effects of a 24-week course of interferon-αtherapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma显示文摘AIM:To assess whether a 24-wk course of interferon (IFN)could prevent hepatocellular carcinoma(HCC) recurrence and worsening of liver function in patients with hepatitis C virus(HCV)-infected patients after receiving curative treatment for primary HCC. METHODS:Outcomes in 42 patients with HCV infection treated with IFN-α,after curative treatment for primary HCC(IFN group),were compared with 42 matched curatively treated historical controls not given IFN(non- IFN group). RESULTS:Although the rate of initial recurrence did not differ significantly between IFN group and non-IFN group (0%,44%,61%,and 67% vs 4.8%,53%,81%,and 87% at 1,3,5,and 7 years,P=0.153,respectively), IFN group showed a lower rate than the non-IFN group for second recurrence(0%,10.4%,28%,and 35% vs 0%,30%,59%,and 66% at 1,3,5 and 7 years, P=0.022,respectively).Among the IFN group,patients with sustained virologic response(SVR)were less likely to have a second HCC recurrence than IFN patients without an SVR,or non-IFN patients.Multivariate analysis identified the lack of SVR as the only independent risk factor for a second recurrence,while SVR and Child-Pugh class A independently favored overall survival. CONCLUSION:Most intrahepatic recurrences of HCV- related HCC occurred during persistent viral infection. Eradication of HCV is essential for the prevention of HCC recurrence and improvement of survival. | Soo Cheol Jeong Hiroshi Aikata Yoshio Katamura Takahiro Azakami Tomokazu Kawaoka Hiromi Saneto Kiminori Uka Nami Mori Shintaro Takaki Hideaki Kodama Koji Waki Michio Imamura Hiroo Shirakawa Yoshiiku Kawakami Shoichi Takahashi Kazuaki Chayama | 2007 | World Journal of Gastroenterology2007，13，40： | 3 |
| 20 | Hepatic Stellate Cells Secrete Angiopoietin 1 That Induces Angiogenesis in Liver Fibrosis显示文摘 | Kojiro Taura Samuele De Minicis Ekihiro Seki Etsuro Hatano Keiko Iwaisako Christoph H. Osterreicher Yuzo Kodama Kouichi Miura Iwao Ikai Shinji Uemoto David A. Brenner | 2008 | Gastroenterology2008，，5： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员